Haryana Resumes Ayushman Bharat Payments, Delays Withdrawal by 650 Private Hospitals

Chandigarh, August 6, 2025 — Hours before a mass withdrawal by 650 private hospitals was set to take effect under Ayushman Bharat – AB‑PMJAY, the Haryana State Health Agency (SHA) confirmed that payment processing has resumed. The release of new funding has halted the immediate threat to suspend services that would have affected 1.8 crore beneficiaries across the state.

 

The SHA began clearing claims on August 4, following receipt of the state’s budget allocation. Hospitals are being paid on a first‑in‑first‑out (FIFO) basis, and claims up to the first week of May 2025 have been settled. SHA officials noted that ₹2,900 crore has been disbursed to hospitals since the scheme launched, including ₹240.63 crore so far.

On July 28, the Haryana chapter of thehttp://Indian Medical Association Indian Medical Association (IMA) issued a warning. It threatened to pull hospitals out of the Ayushman scheme from August 7 if ₹500 crore in unpaid reimbursements were not cleared. Despite some payments, many hospitals had received just 10–15% of their claims since March.

 

SHA Actions and Reforms

 

The SHA has confirmed transparent processes via the National Health Authority (NHA) portal, using a 50-member doctor team to manage claim allocations impartially. Hospitals have an opportunity to upload missing documentation before deductions. If defaults occur, hospitals can appeal via a Medical Audit Committee, and 400 grievances have already been resolved via the CGRMS 2.0 platform.

To deepen transparency, IMA representatives are now included in district and state-level audit and grievance redress committees. NABH incentive applications continue under revised rules via the HEM 2.0 portal, replacing HEM 1.0.

Remaining Risks and Warnings

Despite the progress, IMA Haryana has maintained its stance. Former IMA President Dr Ajay Mahajan emphasised that unless all dues are satisfactorily cleared, hospitals may still withdraw services from August 7, disrupting planned surgeries and inpatient care. Emergency services would continue, but non-critical care may be

This crisis highlights a fragile ecosystem: hospitals provide free care upfront and rely heavily on government reimbursements. Prolonged delays strain operations and threaten the credibility of http://Ayushman BharatAyushman Bharat, India’s flagship universal health coverage programme. Maintaining timely public–private collaboration is essential for sustaining healthcare access across Haryana.

 

Related Posts

World Record in Robotic Tele-Surgery takes Intercontinental Leap of 20,000 Km

SSiMantra, ‘Made in India’ Surgical robot, flourishes another Eye Popping feather in its Cap New Delhi: It seems SSInnovations, maker of surgical robot SSiMantra, knows no bounds in scripting world…

A Non- Smoker Smoking Hot Spouse needed for Actress Neetu Chandra

Hollywood Fame Bihari Babe is still Unwed for being Wedded to ‘No Tobacco’ Cause Mumbai: Marriage Bureau might have to frame a blurb like – A non- smoker smoking hot…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Ajanta Pharma Promoter Sell 3% Stake Worth ₹1,024 Crore; Shares Trade Higher

Ajanta Pharma Promoter Sell 3% Stake Worth ₹1,024 Crore; Shares Trade Higher

FDA cracks down on illegal drug trade, stock worth about ₹25 lakh seized from Pune and Kolhapur

FDA cracks down on illegal drug trade, stock worth about ₹25 lakh seized from Pune and Kolhapur

ICMR-NIN study links micronutrient deficiencies to higher dementia risk

ICMR-NIN study links micronutrient deficiencies to higher dementia risk

Pvt nursing home sealed in Chatra after woman, unborn baby die

Pvt nursing home sealed in Chatra after woman, unborn baby die

30 docs from 9 states guilty of taking pharma company junket, no action yet by 6 state medical councils

30 docs from 9 states guilty of taking pharma company junket, no action yet by 6 state medical councils

Scheme to build bulk drugs’ R&D, capacity in works, says Pharma secy

Scheme to build bulk drugs’ R&D, capacity in works, says Pharma secy